RTTNews | Dec 7, 2021 09:24AM EST

09:23 Tuesday, December 7, 2021 (RTTNews.com) - Anixa Biosciences Inc. (ANIX) and MolGenie said that their COVID-19 compounds are expected to be effective against the Omicron Variant as well as the Delta variant.

The companies noted that they are developing compounds for the potential treatment of COVID-19 with the long-term goal of developing an inexpensive, orally-administered room temperature-stable pill for the outpatient setting.

The program focuses on identifying novel, small molecule inhibitors of Mpro, the main protease of the SARS-CoV-2 virus, which is necessary for replication.

Read the original article on RTTNews ( https://www.rttnews.com/3247477/anixa-covid-19-compounds-expected-to-be-effective-against-omicron-and-delta-variants.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved